Oura's IPO Is a Subscription to Your Own Biology
The filing landed quietly. No fanfare. No press conference. Just a regulatory document that would reshape how we value a company that sells rings.
Oura seeks up to $3 billion in its US IPO. The valuation target: north of $16 billion. For a company that sells a piece of wearable hardware starting at $299, plus a $5.99 monthly subscription to access your own health data.
Let me be precise about what this means. The market is valuing Oura not as a hardware company. Not as a consumer electronics brand. The market is valuing Oura as a data monopoly in formation — a company that has convinced 2.5 million people to pay for the privilege of generating data that Oura owns, analyzes, and monetizes.
I've spent 24 years in this industry. I've audited ICOs that promised less and delivered nothing. I've watched DAOs collapse because they couldn't answer a simple question: who owns the data? Oura's IPO is the clearest signal yet that the consumer health data economy has arrived — and that most users don't understand what they're signing up for.
Verify everything, trust nothing. Let's verify what Oura actually is.
Context: The Ring That Became a Revenue Engine
Oura Health Oy. Founded in 2013 in Oulu, Finland. The company's origin story is almost archetypal: a team of engineers and designers who believed that the finger — not the wrist — was the optimal location for continuous physiological monitoring.
The logic was sound. The finger has a denser network of blood vessels. The fingertip's proximity to the skin's surface allows for more accurate photoplethysmography (PPG) — the optical technique used to measure blood volume changes. The ring form factor is less intrusive than a wristwatch. You can sleep with it. You can forget it's there. That's the entire value proposition.
By 2024, Oura had shipped over 2.5 million rings. Revenue exceeded $500 million, growing more than 50% year-over-year. The company claims over 90% monthly active user retention in its app. Subscription penetration exceeds 60% of hardware owners.
These numbers matter. They tell a story that the IPO valuation amplifies: Oura is not selling hardware. Oura is selling a relationship.
The hardware is the acquisition cost. The subscription is the revenue engine. The data is the moat.
Here's what the market understands that most consumers don't: Oura's gross margins on hardware are estimated at 60-65%. But the subscription revenue — $5.99 per month, or $71.88 annually — carries gross margins above 90%. The subscription is pure software economics layered on top of a hardware acquisition funnel.
Code is the only law that holds. And the code in Oura's case is the algorithm that converts raw physiological signals into actionable health insights. That algorithm is trained on millions of nights of sleep data, hundreds of millions of heart rate measurements, and continuous temperature readings from a diverse global user base.
This is the asset that justifies a $16 billion valuation. Not the rings. The data.
Core: The Subscription Economy's Data Monopoly Problem
Let me break down the mechanics of what Oura has built, because the structural implications extend far beyond one Finnish hardware company.
The Three-Layer Revenue Architecture
Layer 1: Hardware Acquisition. The ring itself. $299-$499 depending on model and finish. This is the customer acquisition cost — borne by the consumer, not the company. Oura's DTC model means no retail markup, no distributor margin. The company captures the full hardware margin while simultaneously acquiring a paying subscriber.
Layer 2: Subscription Revenue. $5.99 per month. This is the recurring revenue stream that transforms Oura from a transactional hardware business into a subscription service. The subscription unlocks "advanced insights" — sleep staging, readiness scores, personalized recommendations. Without it, the ring becomes a glorified step counter.
Layer 3: Data Monetization. This is the layer that isn't in the consumer pitch. Oura's terms of service grant the company broad rights to use aggregated, de-identified user data for research, product development, and potential commercial partnerships. The company has already partnered with pharmaceutical companies and research institutions. The data is the ultimate asset — and it's growing with every night of sleep.
The Structural Problem: You Pay to Generate Data You Don't Own
Here's the uncomfortable truth that the IPO narrative obscures: Oura users are paying for the privilege of generating a valuable asset that they do not own and cannot access without ongoing payment.
Consider the economics from the user's perspective:
- Year 1: $299 (hardware) + $71.88 (subscription) = $370.88
- Year 2: $71.88 (subscription continues)
- Year 3: $71.88 (subscription continues)
By year three, the user has paid over $514 for a device that cost Oura approximately $120 to manufacture. The user's data — thousands of nights of sleep, millions of heart rate measurements, continuous temperature trends — has been used to improve Oura's algorithms, which in turn makes the product more valuable for future subscribers.
The user receives a better product. Oura receives a better algorithm. But the user's data — the raw material for that improvement — remains locked in Oura's ecosystem.
Skepticism is the first line of defense. And skepticism demands we ask: what happens when the user wants to leave?
The answer is stark. The data stays with Oura. The user can export a PDF summary of their health trends. But the raw data — the continuous physiological stream that constitutes the actual value — remains proprietary. The user cannot transfer their data to a competing platform. They cannot take their five years of sleep history to Whoop or Apple. They can only start over.
This is the data lock-in problem that the blockchain community has been warning about for a decade. And Oura's IPO is the moment it goes mainstream.
The Valuation Logic: Why $16 Billion Makes Sense (and Why It's Terrifying)
Let me walk through the valuation math, because it reveals the market's assumptions about the future of health data.
At $16 billion, with 2024 revenue of approximately $500 million, Oura trades at roughly 32x trailing revenue. For context, Apple trades at about 8x revenue. Microsoft trades at about 13x. Even high-growth SaaS companies rarely sustain 30x+ revenue multiples.
The market is pricing Oura as if it will grow into its valuation. The implied trajectory: revenue reaching $2-3 billion within 3-5 years, with subscription revenue becoming the dominant component.
Is this plausible? Let's examine the levers:
Lever 1: Subscription Penetration. Currently at 60% of hardware owners. If Oura can push this to 80% — through aggressive feature gating and personalized upsells — subscription revenue alone could reach $400 million annually at current hardware install base.
Lever 2: Hardware Expansion. The smart ring category is growing at approximately 30% annually. If Oura maintains its 70%+ market share in the category, hardware revenue could double within 3 years.
Lever 3: New Revenue Streams. This is where the valuation gets interesting. Oura has already launched Oura for Business — a B2B2C offering that sells rings and subscriptions to employers for their workforce. The company is exploring medical device certification through FDA clearance. And the data monetization layer — currently underdeveloped — represents a potential revenue stream that could dwarf hardware and subscription combined.
The market is betting that Oura becomes the operating system for personal health data — the platform that aggregates physiological signals, applies AI-driven analysis, and delivers actionable insights across the healthcare ecosystem.
That's the bull case. Here's the bear case.
The Bear Case: What the IPO Narrative Doesn't Tell You
Signal 1: Hardware Saturation. The emphasis on subscription revenue in the IPO narrative suggests that hardware growth is slowing. The smart ring category, while growing, remains niche. Oura's 2.5 million units shipped is impressive for a category pioneer, but Apple ships 50 million watches annually. The category ceiling is real.
Signal 2: Competitive Threat. Samsung entered the smart ring market in 2024 with the Galaxy Ring. Apple's entry is rumored. Both companies have distribution advantages, brand recognition, and — critically — existing health data ecosystems. Oura's category dominance is real, but category dominance in a small category is fragile.
Signal 3: The Data Privacy Reckoning. As consumers become more aware of how their health data is used, the subscription model may face headwinds. Regulatory scrutiny of health data practices is increasing globally. The EU's GDPR and the US's evolving health privacy frameworks could impose constraints on Oura's data monetization ambitions.
Signal 4: The AI Disruption Risk. The core value of Oura's algorithm — converting physiological signals into health insights — is increasingly commoditizable. Foundation models trained on massive health datasets could provide comparable insights without the proprietary data moat. If AI can analyze raw physiological data as effectively as Oura's trained algorithms, the subscription value proposition weakens.
Contrarian: The Case for Decentralized Health Data
Now let me challenge the prevailing narrative — including my own skepticism.
The contrarian view: Oura's centralized model is actually the most pragmatic path to mainstream health data adoption, and decentralization would kill the category.
Here's the argument.
The blockchain community has spent years advocating for self-sovereign identity and user-owned data. The vision: users control their health data, grant access to applications on a permissioned basis, and monetize their data directly.
This vision is philosophically sound. It is practically unproven.
The reality is that most consumers don't want to manage their health data. They want to wear a ring, get a sleep score, and feel better. The subscription model — for all its flaws — provides a simple, predictable value exchange: I pay $5.99 per month, and Oura tells me how to sleep better.
The data ownership problem is real, but it's a second-order concern for most users. The first-order concern is: does this product improve my health?
Governance isn't a feature; it's a verification. And the verification of Oura's value proposition is happening in the market — 2.5 million users, 90% monthly retention, 80% subscription renewal rates. The market is voting with its wallet, and the market is saying: I'll trade my data for better health insights.
This is the uncomfortable truth that decentralization advocates must confront. The centralized model works. It's simple. It's effective. And it's generating real value for users.
The question is whether this model is sustainable — and whether the concentration of health data in a single corporate entity represents a systemic risk that we should accept.
The Systemic Risk Argument
Consider what happens if Oura's data is breached. Or if Oura's algorithms are found to be systematically biased against certain populations. Or if Oura is acquired by a company with different data practices.
The concentration of health data creates a single point of failure — not just for Oura users, but for the broader health data ecosystem. If Oura's data is compromised, millions of people's most intimate physiological data is exposed.
This is the argument for decentralized alternatives. Not because decentralization is inherently superior, but because distributed data ownership reduces systemic risk.
The challenge is that decentralized health data platforms have failed to achieve product-market fit. The user experience is more complex. The value proposition is harder to communicate. And the network effects that make centralized platforms valuable are harder to replicate in decentralized systems.
Takeaway: The Data Ownership Reckoning Is Coming
Oura's IPO is not just a financial event. It's a signal.
The signal is that health data has become the most valuable asset class in consumer technology. And the companies that control health data — not the companies that manufacture hardware — will capture the value.
This has profound implications for the blockchain community. The tools we've built — decentralized identity, verifiable credentials, data marketplaces — are directly relevant to the health data economy. But they will only matter if they can deliver better user experiences than the centralized alternatives.
The question I'm asking myself — and the question I'm putting to you — is this: Can we build a health data ecosystem that gives users the simplicity of Oura and the sovereignty that decentralization promises?
The answer will determine whether the next decade of health technology is controlled by a handful of corporations or distributed across a network of user-owned data.
Oura's $16 billion valuation is the price of centralized health data. The question is whether we're willing to pay it — or whether we can build something better.
Verify everything, trust nothing. The data will tell us which path we're on.